Fostamatinib disodium and Triaminic Long Acting Cough
Determining the interaction of Fostamatinib disodium and Triaminic Long Acting Cough and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Fostamatinib may increase the blood levels and effects of dextromethorphan. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib. According to the product labeling, administration of a single 40 mg dose of the CYP450 3A4 substrate simvastatin with fostamatinib 100 mg twice daily increased simvastatin peak plasma concentration (Cmax) and systemic exposure (AUC) by 113% and 64%, respectively. In addition, simvastatin acid Cmax increased by 83% and AUC increased by 64%. When the P-gp substrate digoxin (0.25 mg once daily) was administered with fostamatinib (100 mg twice daily), digoxin Cmax and AUC increased by 70% and 37%, respectively.
MANAGEMENT: Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.
- "Product Information. Tavalisse (fostamatinib)." Rigel Pharmaceuticals, South San Francisco, CA.
Generic Name: fostamatinib
Brand name: Tavalisse
Synonyms: Fostamatinib disodium (Oral)
Generic Name: dextromethorphan
Brand name: Triaminic Long Acting Cough, Babee Cof, Buckleys Mixture, Creomulsion, DayQuil Cough, Delsym, Robafen Cough Liquidgels, Scot-Tussin Diabetic, Silphen DM, Benylin DM Pediatric, Creo-Terpin, Delsym 12 Hour Cough Relief, Elixsure Cough, Robitussin CoughGels, St. Joseph Cough Suppressant, Sucrets DM Cough, Theraflu Thin Strips Cough, DexAlone, Hold, Sucrets 4-Hour Cough Drops, Robitussin Maximum Strength, Vicks Formula 44
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fostamatinib disodium-Triaminic Multi-Symptom Fever
- Fostamatinib disodium-Triaminic Night Time Cold & Cough
- Fostamatinib disodium-Triaminic Softchew Throat Pain and Cough
- Fostamatinib disodium-Triaminic Softchews Allergy Congestion
- Fostamatinib disodium-Triaminic Softchews Allergy Sinus
- Fostamatinib disodium-Triaminic Softchews Chest Congestion
- Triaminic Long Acting Cough-Fosteum
- Triaminic Long Acting Cough-Fostex
- Triaminic Long Acting Cough-Fostex Cream Topical
- Triaminic Long Acting Cough-Fostex Medicated
- Triaminic Long Acting Cough-Fostex Wash 10%
- Triaminic Long Acting Cough-Fototar